Danaher (DHR) Q1 FY26 earnings call

Danaher delivered a resilient start to the year: end-market momentum broadly improved and cost execution drove earnings ahead of plan even as a weak respiratory season masked headline core growth. Management holds its full-year core-growth range while pointing to a bioprocessing equipment-order inflection and a China recovery as the levers for a second-half acceleration, with the pending Masimo deal and balance-sheet capacity keeping M&A the priority use of capital.